☆ 4.7 Article

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+HER2-metastatic breast cancer

BIOMEDICINE & PHARMACOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, Research & Experimental

Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure

Rossana Roncato et al.

Summary: This study investigated the impact of BMI on the safety and efficacy profile of palbociclib in patients with metastatic luminal-like breast cancer. Patients with BMI <25 had higher incidences of hematologic toxicities, dose reduction events, and lower dose intensities, as well as shorter progression-free survival compared to those with BMI ≥25.

BIOMEDICINE & PHARMACOTHERAPY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites

Alejandra Martinez-Chavez et al.

Summary: The study reveals that both ABCB1 and ABCG2 proteins profoundly limit the brain penetration of abemaciclib and its active metabolites, and are likely involved in their elimination through the liver, bile, or intestines. Additionally, the human CYP3A4 gene significantly reduces the plasma concentration of abemaciclib, highlighting its importance in the clinical development of abemaciclib for brain malignancies.

PHARMACOLOGICAL RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Real world incidence and management of adverse events in patients with HR+, HER2-metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting

Gregory L. Price et al.

Summary: This study analyzed data from 396 patients with HR+, HER2-, MBC who received CDK4 and 6 inhibitors, and found that the frequencies of adverse events were lower compared to clinical trials, but dose reductions due to adverse events were higher. Clinicians may proactively manage adverse events to help patients continue therapy.

CURRENT MEDICAL RESEARCH AND OPINION (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib

Akimitsu Maeda et al.

Summary: The ABCB1 2677G > T/A polymorphism may predict the pharmacokinetics and tolerability of abemaciclib.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

Rossana Roncato et al.

Summary: This study presents a case series of breast cancer patients treated with CDK4/6 inhibitors and provides an intensified pharmacological approach to support clinicians in the management of CDKi treatment. The study shows the importance of therapeutic drug monitoring, pharmacogenetics, and drug-drug interaction analysis in optimizing CDKi therapy.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia

Anna Marta Madejczyk et al.

Summary: This study assessed the impact of inherited variants in ABCB1, ABCG2, PXR, and CAR genes on the efficacy and toxicity of dasatinib therapy in CML patients, and found multiple SNPs associated with treatment response and prognosis.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

C. Louwrens Braal et al.

Summary: CDK 4/6 inhibitors are a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. This article reviews the clinical pharmacokinetic and pharmacodynamic profiles of these inhibitors and discusses important future directions for their clinical applicability.

DRUGS (2021)

添加到收藏夹

Article Biochemical Research Methods

A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer

Ariana Soledad Poetto et al.

Summary: Therapeutic drug monitoring (TDM) is essential for defining proper drug dosage in cancer treatment. A new LCMS/MS method for analyzing DBS samples containing PALBO, RIBO, and LETRO has been developed to improve the accuracy of drug exposure monitoring. This method is fast, easy, and reproducible for clinical use.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)

添加到收藏夹

Article Oncology

Dose modifications of ribociclib and endocrine therapy for treatment of ER+HER2-metastatic breast cancer

Kristoffer B. Kristensen et al.

Summary: A retrospective cohort study on 128 patients with ER+ HER2- MBC undergoing ribociclib treatment showed that dose reduction did not compromise treatment efficacy, and supported the translation of results from the MONALEESA trials to real-world clinical settings. Adverse events were consistent with previous reports, and factors such as type of endocrine therapy and baseline lymph node involvement affected the likelihood of requiring a dose reduction.

BREAST CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3

Hiroji Iwata et al.

Summary: The most common treatment-related adverse event in clinical trials with the CDK4/6 inhibitor palbociclib is neutropenia. Low baseline absolute neutrophil count was identified as a strong independent risk factor for grade 3/4 neutropenia, and genetic variants in ABCB1 and ERCC1 may play a role in its occurrence. Pharmacogenetic testing could inform clinicians about the likelihood of severe neutropenia with palbociclib.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

Federica Loscocco et al.

Summary: This study identified associations between specific ABCC2 and ABCB1 gene SNPs and achievement of deep molecular responses in CML patients, as well as connections between certain ABC transporter gene SNPs and the maintenance or loss of molecular responses. The study also developed a predictive model incorporating information on four genotypes, which was found to have high prognostic significance for both achieving and maintaining molecular responses.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib

Natansh D. Modi et al.

Summary: This study found that older age is significantly associated with an increased risk of grade > 3 diarrhoea induced by abemaciclib. A clinical prediction tool, defined by race, ECOGPS, and pre-treatment white blood cell count, effectively discriminated subgroups with different risks of grade >3 neutropenia following abemaciclib initiation.

BREAST (2021)

添加到收藏夹

Meeting Abstract Oncology

Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).

Lorenza Palmero et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application

Bianca Posocco et al.

PLOS ONE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations

Florent Ferrer et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Rossana Roncato et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Editorial Material Oncology

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2-Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial

Veronique Dieras et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Medicine, Research & Experimental

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability

Alejandra Martinez-Chavez et al.

MOLECULAR PHARMACEUTICS (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro

Ales Sorf et al.

BIOCHEMICAL PHARMACOLOGY (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach

Wan Sun et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Oncology

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

Sunil Verma et al.

ONCOLOGIST (2016)

添加到收藏夹

Article Oncology

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib

Mark C. de Gooijer et al.

INVESTIGATIONAL NEW DRUGS (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Thomas J. Raub et al.

DRUG METABOLISM AND DISPOSITION (2015)

添加到收藏夹

Article Oncology

ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib

Douglas Vivona et al.

ONCOLOGY LETTERS (2014)

添加到收藏夹

Article Oncology

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Keith T. Flaherty et al.

CLINICAL CANCER RESEARCH (2012)

添加到收藏夹

Article Oncology

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

Suman Lal et al.

CANCER SCIENCE (2008)

添加到收藏夹

Article Pharmacology & Pharmacy

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin

J. E. Keskitalo et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)

添加到收藏夹

Article Oncology

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Jing Li et al.

CANCER BIOLOGY & THERAPY (2007)

添加到收藏夹

Article Pharmacology & Pharmacy

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

Erin R. Gardner et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.